Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Piper Sandler

Micron Shares Drop Following This Analyst Downgrade - Read Why

Piper Sandler analyst Harsh Kumar downgraded Micron Technology, Inc (NASDAQ:MU) from Neutral to Underweight and lowered the price target from $90 to $70. Kumar expressed concerns about Micron's over 50% exposure to consumer-like markets such as PCs, mobile, and others when the global economy will likely face headwinds. Kumar expects the company's chip business catering…

Benzinga

Why Nvidia Shares Are Diving Today

Shares of semiconductor companies, including NVIDIA Corporation (NASDAQ: NVDA), are trading lower in sympathy with Micron, which dipped following a downgrade and price target cut from Piper Sandler analysts.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Tesla's Model Y Lead Times In Germany Have Spiked By Over 50%

Tesla, Inc.

Benzinga

Is 2U Stock a Buy Under $10?

The shares of the education technology company 2U (TWOU) plunged in price after Piper Sandler analysts downgraded the stock. TWOU closed the last trading session at less than $10. However, considering the company’s significant operational prospects with its EdX acquisition, is the stock a buy now? Keep reading to learn…

StockNews.com

Here's Why Analysts Had Mixed Opinions On C3.ai Post Q4 Results

Analyst opinions remained mixed about C3.ai, Inc (NYSE:AI) following its dismal FY23 guidance despite a Q4 beat. Piper Sandler analyst Arvind Ramnani downgraded C3.ai from Overweight to Neutral and slashed the price target from $28 to $15. The re-rating reflected lackluster guidance triggered by enterprise spending softness, slower customer growth, and a dismal demand. Ramnani noted the…

Benzinga

Read How Analysts Reacted To MongoDB Post Q1 Earnings Beat

Analysts appreciated MongoDB, Inc's (NASDAQ:MDB) Q1 beat but cut the price target to reflect macro headwinds. Needham analyst Mike Cikos maintained MongoDB with a Buy rating and lowered the price target from $362 to $310. The price target change reflected the declines in the broader stock market. Cikos acknowledged MongoDB's strong 1QF23 feat outperforming guidance and expectations.…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

Benzinga

What's Going On With Chewy Stock Today?

Chewy Inc (NYSE: CHWY) shares are trading lower Wednesday after Piper Sandler cut its price target ahead of the company's earnings results.

Benzinga

9 Salesforce Analysts React To Q1 Earnings Beat: 'Next Quality Software GARP Stock'

Salesforce Inc (NYSE: CRM) shares jumped Wednesday morning after the company reported first-quarter earnings and raised its profit forecast.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Upgrades

Benzinga

What Are Whales Doing With Advanced Micro Devices

Someone with a lot of money to spend has taken a bullish stance on Advanced Micro Devices (NASDAQ:AMD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Why Piper Sandler Downgrades 2U: Elevated Downside Risk Among Other Factors

There is downside risk to 2U Inc’s (NASDAQ: TWOU) stock from the regulatory overhang and various headwinds facing the industry, according to Piper Sandler.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Piper Sandler Lists What Could Go Right For Bill.Com

Piper Sandler analyst Brent Bracelin maintained Bill.Com Holdings, Inc (NYSE:BILL) with an Overweight and lowered the price target from $300 to $205 (92.4% upside). After six months of fielding investor questions, Piper Sandler published a new 'what could go right?' report series. The report involved in-person meetings with senior leadership to understand better how different cloud business…

Benzinga

10 Biggest Price Target Changes For Tuesday

Needham reduced WalkMe Ltd. (NASDAQ: WKME) price target from $40 to $20. WalkMe shares dropped 8.1% to close at $12.20 on Monday.

Benzinga

Piper Sandler Maintains Neutral Rating for Marathon Petroleum: Here's What You Need To Know

Piper Sandler has decided to maintain its Neutral rating of Marathon Petroleum (NYSE:MPC) and raise its price target from $96.00 to $106.00. Shares of Marathon Petroleum are trading up 2.15% over the last 24 hours, at $98.64 per share.

Benzinga

Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24 hours, at $5.26 per share. A move to $25.00 would account for a 375.29% increase from the current…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022

Benzinga

Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know

Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over the last 24 hours, at $5.68 per share.

Benzinga

10 Biggest Price Target Changes For Thursday

Wells Fargo cut the price target on Ford Motor Company (NYSE: F) from $24 to $12. Ford shares fell 2.8% to $12.47 in pre-market trading.

Benzinga

Piper Sandler Maintains Overweight Rating for Beauty Health: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Beauty Health (NASDAQ:SKIN) and lower its price target from $26.00 to $24.00. Shares of Beauty Health are trading down 0.76% over the last 24 hours, at $12.40 per share.

Benzinga

Why These Analysts Cut Unity Software Price Target By 50%

Shares of Unity Software Inc (NYSE: U) tanked more than 30% after the company reported a wider-than-expected net loss for the first quarter and issued weak revenue guidance.

Benzinga

What Are Whales Doing With Palantir Technologies

Someone with a lot of money to spend has taken a bearish stance on Palantir Technologies (NYSE:PLTR). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.